FDA approves new indication for Merck's Emend

4 February 2016

The US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for single-dose Emend (fosaprepitant dimeglumine) for injection.

Emend, Merck & Co’s (NYSE: MRK) substance P/neurokinin-1 (NK1) receptor antagonist, in combination with other antiemetic medicines, is now cleared for the prevention of delayed nausea and vomiting in adults receiving initial and repeat courses of moderately emetogenic chemotherapy (MEC). Emend has not been studied for the treatment of established nausea and vomiting.

The FDA approval is supported by data from a Phase III study that showed single-dose Emend for injection, combined with other anti-vomiting medicines, provided greater protection from delayed nausea and vomiting following administration of moderately emetogenic chemotherapy versus an active control regimen. With this approval, Emend for injection is the first intravenous single-dose NK1 receptor antagonist approved in the USA for both highly emetogenic chemotherapy (HEC) as well as MEC.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK